Cancer / Immunology

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

 September 11, 2026 | News

Kazia Doses First Patient in Phase II Study of Paxalisib Combination for Aggressive Paediatric Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies cur...

 September 11, 2026 | News

EpiVax Adds AI-Enabled Enhancements to ISPRI Immunogenicity Risk Platform

EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the ...

 September 04, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

 September 03, 2026 | News

US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma

T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation ...

 September 02, 2026 | News

DarwinHealth Unveils AI-Powered ‘Quantum Cancer Biology’ Framework to Decode Drug-Resistant Tumours

New paradigm integrates single-cell transcriptomics, regulatory network inference, and AI to decode—and therapeutically target—the multiple, co...

 August 28, 2026 | News

US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...

 August 27, 2026 | News

Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours

Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Coll...

 August 25, 2026 | News

US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging

 NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food ...

 August 21, 2026 | News

Optellum, Coreline Soft Join Forces to Build Integrated AI Pathway for Lung Nodule Care

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform &nbs...

 August 17, 2026 | News

China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer

Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...

 August 13, 2026 | News

HanchorBio Partners with Taiwan Cancer Moonshot Team to Advance Precision Immunotherapy

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate bioma...

 August 11, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

 August 11, 2026 | News

Innovent Doses First Patient in Phase 3 Trial of IBI363 for Advanced Colorectal Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

 August 07, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close